Neurodegeneration with Brain Iron Accumulation

Neurodegeneration with brain iron accumulation is a group of rare, genetically heterogeneous neurodegenerative disorders. They are unified by abnormal iron accumulation within specific basal ganglia structures (predominantly the globus pallidus and substantia nigra) on neuroimaging.

The clinical picture combines progressive movement disorder (typically dystonia, parkinsonism, or both). Many subtypes add cognitive decline, spasticity, and retinal or optic nerve involvement.

Pantothenate kinase associated neurodegeneration (caused by mutations in the PANK2 gene) is the commonest and most extensively characterised subtype within this genetically diverse group.

Pathophysiology and genetic heterogeneity

• The underlying genetic defects across this group affect diverse cellular pathways, including coenzyme A biosynthesis (pantothenate kinase associated neurodegeneration), lipid metabolism, and iron homeostasis and autophagy regulation.
• The shared downstream consequence is pathological iron accumulation within specific basal ganglia structures. The relationship between the genetic and metabolic defect and the resulting iron accumulation varies between subtypes and remains incompletely understood for several of the rarer forms.
• Pantothenate kinase associated neurodegeneration results from mutations in PANK2, encoding an enzyme essential for coenzyme A biosynthesis.
• Classical, earlier onset disease is generally associated with more severe, complete loss of enzyme function. Atypical, later onset disease is generally associated with partial, residual enzyme activity. This correlates broadly with disease severity and rate of progression.

• Classical pantothenate kinase associated neurodegeneration typically presents in early childhood with progressive dystonia (often beginning in the lower limbs and progressively generalising), together with dysarthria, spasticity, and, over the disease course, significant cognitive decline.
• Rapid progression to severe disability over the subsequent one to two decades is characteristic of this severe phenotype.
• Atypical, later onset disease presents in later childhood, adolescence or, less commonly, adulthood, with a generally more slowly progressive course. This reflects the generally milder underlying enzymatic deficit.
• Prominent psychiatric and behavioural features (including impulsivity and personality change) often accompany the movement disorder in the atypical phenotype.
• Pigmentary retinopathy, producing progressive visual impairment, is a characteristic additional feature in a substantial proportion of cases, particularly the classical phenotype. It is a useful clinical clue supporting this diagnosis within the broader disease group.
• Other genetic subtypes produce variable additional clinical features according to the underlying gene and mechanism. These include, in certain subtypes, optic atrophy, motor neuropathy, or a more prominent parkinsonian phenotype.
• The clinical pattern together with the imaging appearance guides toward the likely genetic subtype requiring targeted confirmatory testing.

• Magnetic resonance imaging demonstrating characteristic abnormal iron accumulation within the globus pallidus (and, in some subtypes, the substantia nigra) is central to diagnosis.
• The "eye of the tiger" sign comprises a central area of relative T2 hyperintensity surrounded by a rim of pronounced hypointensity within the globus pallidus. It is a classically described and highly suggestive, though not universally present, finding, particularly associated with pantothenate kinase associated neurodegeneration.
• Genetic testing, directed by the clinical phenotype and imaging pattern, confirms the genetic subtype. A multigene panel approach is increasingly used given the substantial genetic heterogeneity, allowing simultaneous testing for the range of genes associated with this phenotypic and radiological pattern.
• Full clinical assessment supports both diagnostic classification and ongoing monitoring of disease progression.
• It includes formal ophthalmological evaluation for retinal or optic nerve involvement, and neuropsychological assessment characterising the pattern and severity of cognitive involvement.
• It also includes detailed movement disorder assessment characterising the combination and relative prominence of dystonia, parkinsonism and spasticity present.

• There is no currently available disease modifying treatment for any subtype within this group. Management is therefore predominantly symptomatic, addressing the movement disorder, cognitive, and other clinical manifestations present in the individual patient.
• Dystonia management follows general principles applicable to dystonia from any cause. Options include oral pharmacological agents (trihexyphenidyl, baclofen) and botulinum toxin injection for focal or segmental dystonia causing particular functional impairment or pain.
• For severe, generalised, medication refractory dystonia, deep brain stimulation (targeting the globus pallidus internus) is an option. It has shown meaningful benefit in appropriately selected patients with pantothenate kinase associated neurodegeneration and severe dystonia, an important treatment option for this severely disabling manifestation.
• Spasticity is managed with standard antispasticity medication and physiotherapy, following the general principles applicable to spasticity from any cause.
• Psychiatric and behavioural symptoms, particularly prominent in atypical, later onset pantothenate kinase associated neurodegeneration, are managed with appropriate psychiatric assessment and, where indicated, pharmacological and behavioural management strategies.
• Provide family and carer support, given the significant impact of these manifestations on daily functioning and family dynamics.
• Multidisciplinary supportive care is an essential and central component of long term management, given the progressive, currently incurable nature of this disease group. It includes physiotherapy, occupational therapy, speech and language therapy, and nutritional support.
• Speech and language therapy is particularly relevant given the frequent dysarthria and, in more advanced disease, dysphagia with associated aspiration risk requiring specific assessment and management.
• Genetic counselling for the family is an important component of management. It includes consideration of testing for at risk relatives and reproductive counselling regarding recurrence risk, given the generally autosomal recessive inheritance pattern of the great majority of subtypes.
• Specialist neurology, genetics, and, where relevant, movement disorder specialist input is essential given the complexity and rarity of these conditions.